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Context: Lactation causes a delay in ovulation in the postpartum period, and therefore a delay in the resumption of menses. However, return
to fertility is variable in the postpartum period and is contingent upon numerous factors. The postpartum period is therefore a critical time to
initiate effective contraception in order to support the numerous beneficial health outcomes of optimal pregnancy spacing. Breastfeeding
women have an unmet need for highly effective birth control methods that do not interfere with lactation and that are safe for their infants.
The progesterone-releasing vaginal ring (PVR) releases a natural progesterone that suppresses ovulation and is specifically designed for
breastfeeding women in the first postpartum year.
Objective: To review the published peer-reviewed literature regarding the safety and effectiveness of the PVR used for contraception among
lactating women, as well as the safety for their infants. Results of this review informed the decisions of the Guideline Development Group to
include recommendations on contraceptive eligibility for the PVR within the World Health Organization Medical Eligibility Criteria for
Contraceptive Use, 5th Edition.
Methods: We searched the PubMed, Popline, and LILACS bibliographic databases for articles published in any language from database
inception through October 1, 2014. We reviewed the literature for evidence regarding the safety of the PVR among breastfeeding women using
the method, as well as for their infants. The US Preventive Services Task Force system was applied to assess the quality of the evidence.
Results: Seven articles met our criteria for inclusion in this review. All studies were of a prospective cohort design. All studies consistently
showed that use of the PVR among breastfeeding women compares favorably to other methods of contraception with regard to effectiveness,
does not compromise a woman’s breastfeeding performance, and does not adversely affect infant growth during the first year postpartum.
Conclusion: The PVR is a safe and highly effective method of contraception for use among breastfeeding women. It should be offered to
women who plan to breastfeed in the context of postpartum contraceptive counseling.
© 2016 Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Progesterone vaginal ring; Lactation; Breastfeeding; Contraception1. Introduction
Worldwide, postpartum women represent a large propor-
tion of women who have an unmet need for family planning
services. Failure to meet the contraceptive needs of these
women results in adverse outcomes for women, their infants,☆ Disclaimer: The findings and conclusions in this report are those of
the authors and do not necessarily represent the official position of theWorld
Health Organization.
⁎ Corresponding author. Tel.: +1-505-925-0688; fax: +1-505-925-0689.
E-mail address: scarrgo66@gmail.com (S.L. Carr).
http://dx.doi.org/10.1016/j.contraception.2015.04.001
0010-7824/© 2016 Published by Elsevier Inc. This is an open access article under the Cand their families. Recognizing the imperative to reach
women in the postpartum period, the 2012 London Summit
on Family Planning included a prioritization on expanding
services and methods to this vulnerable population [1,2].
Lactational amenorrhea (LAM) is one method of
contraception available to those women who choose to
breastfeed. In addition to a host of well-documented
maternal and child health benefits, LAM is approximately
98% effective in preventing pregnancy, provided that
women adhere to three criteria: (1) menstruation has not
resumed, (2) the infant is fully or nearly fully breastfeeding,
and (3) the infant is less than 6 months of age [3]. While this
method is safe and effective, LAM offers only short-term
protection against unplanned pregnancy. At any time aC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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on LAM for contraception, transition to other effective
methods is key to preventing unintended pregnancy during
the postpartum period. Many women discontinue fully
breastfeeding before 6 weeks postpartum and will be at
risk for rapid repeat pregnancy [4], even though the majority
of women do not wish to conceive again during their first
postpartum year [5]. In addition, multinational survey data
from developing countries reveal that breastfeeding and/or
postpartum amenorrhea are cited as a primary reasons for not
using a contraceptive method [6]. Therefore, it is critical to
provide women with options for early initiation of
contraception in the postpartum period to prevent unplanned
and rapid repeat pregnancies.
The progesterone-releasing vaginal ring (PVR) is a contra-
ceptive device that was specifically designed for use among
breastfeedingwomen in order to expand themethodmix for this
population. Safety and efficacy trials have been carried out in
Latin America where it is approved and currently in use in nine
countries [7]. The device is manufactured in Chile under the
trade name “Progering®”. The silicone-elastomer ring has a
cross-sectional diameter of 8.4 mm, has an overall diameter of
58 mm, and contains micronized progesterone (P) that is
released at an average rate of 10 mg/day over a 90-day period.
The ring is designed for 6 months continuous use for women
breastfeeding at least four times per day, with infrequent
removal approved for 2 h maximum. The non-oral delivery
systemof the PVRallows for a sustained release ofmicronized P
at levels sufficient to inhibit ovulation and extend the period of
lactational amenorrhea [7,8]. During proper use, an average
plasma concentration of 20 nmol/L is achieved, which is similar
to that detected in the average luteal phase among normally
ovulating women. The critical P threshold required to inhibit
ovulation during breastfeeding is 10 nmol/L [9]. In a phase 2
clinical trial that assessed extending use of the PVR to 4months,
mean P levels decreased from 17±1 to 14±1 nmol/L (mean±
S.E.), still within the range to inhibit ovulation [10].With regard
to infant exposure to P via the breast milk of mothers who use
the PVR, ingestion of 600mL of breast milk per daywill expose
infants to approximately 4.2 mcg of P [11,12]. This amount is
well below the recommended maximum intake of 150 mcg/day
as per the European Medicines Agency [13]. In addition, P is
rapidly degraded after ingestion and has a very short half-life of
3–90 min, thus conferring additional reassurance of lack of
exposure to exogenous hormones for infants whosemothers use
the PVR [13].
The World Health Organization (WHO) convened
meetings of its Guideline Development Group (GDG)
during March 9–12, 2014 and September 24–25, 2014.
The purpose of these meetings was to review and, where
appropriate, revise specific evidence-based recommenda-
tions included in the WHO Medical Eligibility Criteria
(MEC) for Contraceptive Use. The GDG consisted of 62
participants from 25 countries including experts in interna-
tional family planning and HIV, clinicians, epidemiologists,
researchers, program managers, policymakers, guidelinemethodologists, reproductive biologists, and pharmacolo-
gists. In order to consider eligibility for inclusion of the PVR
in the fifth edition of the MEC guidelines, we conducted this
systematic review of the evidence regarding the safety and
efficacy of the PVR for use among breastfeeding women.2. Methods
We searched the PubMed, Popline, and LILACS biblio-
graphic databases for articles published in peer-reviewed
journals in any language from database inception through
October 1, 2014 for evidence reporting data addressing the
safety of PVR use among breastfeeding women. The
following search terms were applied: “Progesterone”[Mesh]
AND “Contraceptive Devices, Female”[Mesh] for PubMed;
Progesterone, vaginal rings, safety for Popline; and anillo
vaginal, Progestina, and Progesterona for LILACS. In
addition, a search of the International Clinical Trials Registry
Platform (http://apps.who.int/trialsearch/) was performed to
identify completed and ongoing trials investigating the safety
of PVRs for women who are breastfeeding. Reference lists
from articles identified by the search, as well as key review
articles, were hand-searched to identify additional articles.
2.1. Study selection
We reviewed titles as well as abstracts to identify primary
reports of studies investigating the safety of PVR use among
breastfeeding women of any age or parity. Specifically, we
sought to answer the following key question: Among
breastfeeding women and their infants, does the use of the
PVR, compared with non-use of progestogen-only contra-
ceptive methods, affect maternal health, breastfeeding
performance, and infant health? Articles reporting outcomes
related to safety, breastfeeding performance (e.g. duration of
lactation, continuation, supplementation), infant health (e.g.
growth, development, or adverse health events), as well as
contraceptive effectiveness were selected for inclusion in this
review. In addition, studies reporting on these outcomes
among women using the PVR with medical conditions or
characteristics currently included in the MEC were of
interest. Unpublished studies, conference presentations,
review articles, commentaries, and dissertations were
excluded. Articles addressing combined estrogen–progesto-
gen vaginal rings or dosing patterns that differed from the
current 3-month PVR labeling instructions were excluded.
2.2. Study quality assessment
The quality of each individual piece of evidence was
assessed using the United States Prevention Task Force
grading system [14]. Evaluation criteria included the
following: type of study design; sample size and represen-
tativeness; maintenance of comparable groups; extent of loss
to follow-up; completeness of outcome measurement; and
adjustment for confounders.
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Two authors (MG and SC) participated in summarizing
and systematically assessing the evidence through the use of
standard abstract forms [15]. Results from the seven articles
included in this review are presented in Table 1. We did not
compute summary measures of associations due to hetero-
geneity across study designs, study populations, outcome
measures collected, and attrition rates within groups across
the studies.3. Results
Our search strategy identified 679 articles. Following a
review of titles and abstracts, or a full article when necessary,
seven articles satisfied the review inclusion criteria [16–22].
Studies were excluded primarily because either breastfeed-
ing women were not included in the study populations or the
investigations focused on progestogen-only contraceptive
methods but did not address PVRs.
All seven studies applied a prospective cohort design; no
randomized controlled trials were identified. Each study
enrolled healthy, fully breastfeeding volunteers between the
ages of 18 and 38 years who delivered healthy singletons.
Contraception initiation ranged from 5 to 9 weeks postpar-
tum. Follow-up of women and their infants varied; three
studies followed them through 12 months post-initiation of
the chosen contraceptive method [18,20,21], three studies
followed them through 12 months postpartum [16,17,19],
and one study followed them through 12 months after
weaning [22]. Four studies presented comparisons on
outcomes between women who self-selected to use either
the PVR or the copper-containing intrauterine device
(Cu-IUD) [16,18,20,21]. The remaining three studies
compared PVR users with women who elected to use the
Cu-IUD, the six-rod levonorgestrel subdermal implant (LNG
implant), LAM, or progestogen-only pills (POPs)
[17,19,22]. Four of the seven studies were conducted in
public sector clinics in Latin America [16,19,21,22].
All seven studies reported on pregnancy outcomes, infant
weight gain, and method discontinuation/continuation. Six
studies examined lactation performance and occurrence of
side effects and/or adverse events such as device expulsion.
Four studies investigated bleeding patterns. One study
specifically assessed measures of bone metabolism and
bone density during breastfeeding and 6–12 months after
weaning. With respect to the various conditions or
characteristics published within the MEC, all seven studies
reported evidence for the condition, “breastfeeding”, and one
study provided evidence on measures of bone health for the
age subcategory of 18–35 years.
3.1. Contraceptive effectiveness
Two studies reported no pregnancies during 12 months of
follow-up among women who chose to use either the PVR orCu-IUD [20,21]. Similarly, another study reported no
pregnancies among PVR or Cu-IUD users at 12 months;
however, 50 pregnancies occurred among women in this
study who elected other contraceptive methods (2 among
POP users and 48 among users who initially elected LAM,
respectively) [19]. The remaining four studies observed one
pregnancy in the PVR group compared with none observed
among either Cu-IUD users [16,18,22] or LNG implant users
[22]. Two studies recorded pregnancy rates at 12 months
among PVR volunteers of 1.5/100 [18] and 3.5/100 [22].
One pregnancy was observed during 739 woman-months of
exposure in one of the studies [16] and 1007 woman-months
of exposure in another study [17].
3.2. Breastfeeding performance
Among six studies evaluating the effect of PVR use on
various measures of breastfeeding performance in compar-
ison with women using nonhormonal contraception or other
types of progestogen-only contraception (depending upon
the particular study design), no significant differences were
reported. Three studies examined duration of lactation
among Chilean women using the following: the PVR,
Cu-IUD, or LNG implant [22]; PVR, Cu-IUD, POPs, and
LAM [18]; and PVR and Cu-IUD [16]. No significant
differences in lactation duration were recorded in any of
these studies. Similarly, two studies found no difference in
the proportion of women who were fully breastfeeding at
either 6 months postpartum among PVR, Cu-IUD, or LNG
implant users [22] or 14 months post-recruitment among
PVR and Cu-IUD users [21]. Two studies examined whether
differences in the number of breastfeeding episodes occurred
among PVR users compared with women using other
contraceptive methods. In general, no significant differences
were noted at 12 months follow-up between PVR and
Cu-IUD users enrolled in a large multicountry study;
however, PVR users reported a slightly higher number of
breastfeeding episodes per day compared with Cu-IUD users
at 183 days postpartum (8.3 vs. 7.9, respectively; pb.05)
[18]. The other study that assessed the number of
breastfeeding episodes did not show any significant
differences between PVR and Cu-IUD users at 14 months
postpartum [21]. Lastly, no differences on the introduction of
supplementary foods were observed among women using the
PVR or Cu-IUD in a study conducted in Egypt [17].
3.3. Infant health
All seven studies included in this review monitored infant
weight gain during study follow-up. Weight gain, either
absolute or average, did not differ among infants whose
mothers used the PVR compared with infants whose mothers
used nonhormonal contraceptives or other progestogen-only
methods across three studies conducted in Chilean health
centers [16,21,22]. Moreover, no statistically significant
differences in infant weight gain were observed among PVR
users compared with women using a Cu-IUD [17,19,20], an
Table 1
Evidence for the progesterone-releasing vaginal ring.
Author year, source of
support, location
Study design Outcome measures Results Strengths/weaknesses Quality
Diaz S, 1999
Population Council
Chile
Prospective cohort study
LNG implant (N=36)
PVR (N=36)
Cu-IUD (N=57)
Initiated 57±3 days postpartum
Lactating, 18–35 years, normal vaginal
delivery of healthy singleton 38–40
weeks
Bone evaluation at 1, 6, 12 months
postpartum and 6 (PVR), 12 (LNG
implant, Cu-IUD)months after weaning
Pregnancy
Lactation performance: duration
Infant health: weight
Bone density (dual-energy X-ray
absorptiometry)
Biochemical measures of endocrine
function and nutritional status
One pregnancy in PVR group (1/28),
no pregnancies in Cu-IUD (0/48), or
LNG implant (0/24) groups.
Significant differences in mean months
of LAM between PVR and LNG
implant vs. Cu-IUD (12, 12, and 7
months, respectively).
No difference in mean infant weight at
months 1, 6, and 12 months; % fully
breastfeeding at 6 months.
No difference in any bone density
measures after contraceptive initiation;
lumbar spine significantly lower at 1
month postpartum in all groups vs.
nonbreastfeeding women (pb.05), no
difference after weaning.
Biochemical values similar across three
groups; borderl ine significant
difference in parathyroid hormone
between LNG implant vs. PVR and
Cu-IUD (p=.047).
Bone metabolism did not differ
between groups, except alkaline
phosphatases were lower in PVR vs.
Cu-IUD at 6 months.
Strengths:
Detailed clinical and biochemical
measures collected
Weaknesses:
Few measures of infant health
Limited information on method use
16% loss to follow-up
Small sample size
PVR group 78% (N=22) using other
methods at postweaning bone density
measurement.
II-2, fair
Massai R, 1999
USAID
Chile
Prospective cohort; pharmacokinetic
study and clinical trial
PVR (N=285)
Cu-IUD (N=262)
Initiated 5–9 weeks postpartum
Follow-up at 1, 3, 6, 9, 12 months
postmethod initiation, until weaning,
or use of 4 rings
Lactating, 18–38 years, normal
vaginal delivery of healthy singleton
38–40 weeks
Pregnancy
Lactation performance: nursing
frequency
Infant health: weight
Adverse events: colposcopic
vaginal epithelium evaluation:
PVR=45, Cu-IUD=54.
Method continuation
No pregnancies observed over 2320
women-months exposure (PVR); 2183
women-months exposure (Cu-IUD).
No differences between groups for %
fully breastfeeding or number of
breastfeeding episodes at 14 months.
LAMmean duration: PVR=361±9 days
vs. Cu-IUD=198±8 days (pb.01).
No significant differences in monthly
infant weight or mean weight increases
between groups.
Vaginal complaints, urinary discomfort,
urinary infections higher in PVR group
(p=.005); low abdominal pain and
menstrual problems higher in Cu-IUD
group (pb.01); cervical intraepithelial
neoplasia stage 1 (HPV) in 3 PVRusers.
Minor vaginal alterations in 8/45 PVR
users and 2/54 Cu-IUD users. PVR:
vaginal abrasions (n=2); one women
Strengths:
Low loss to follow-up (3%),
nondifferential by method
Weaknesses:
Timing of initiation of method varied
among volunteers
Self-reported bleeding, nursingoutcomes
Differential continuation rates,
differential loss to follow-up within
groups
Mean weight significantly higher among
PVR users compared with Cu-IUD users
(62.6±9 kg vs. 60.2±8 kg)
II-2, fair
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with small asymptomatic abrasion, one
women had extended area abrasion that
regressed with ring removal and normal
after 3 months; 6 women had minor
abrasions. Cu-IUD: one woman with
hyperemia at 6 months, one woman
with petechiae at study discontinuation
Continuation significantly lower in
PVR group at 3, 6 months (86.7% vs.
95%, 66.8% vs. 78.5%), p=.001; NS at
9 months.
Reasons for discontinuation: method
use problems (26.8% PVR vs. 2.3%
Cu-IUD), p=.001; loss to follow-up
(5.2% PVR vs. 16.2% Cu-IUD), p=
.0004; personal (10.1% PVR vs. 2.2%
Cu-IUD), (p=.004)
Chen JH, 1998
Population Council
China
Prospective cohort study
PVR (N=100)
Cu-IUD (N=97)
Initiated 29–64 days postpartum
Follow-up at 1, 3, 6, 9, 12 months
postmethod initiation (clinic or home)
Lactating, 18–35 years, normal delivery
of healthy singleton 38–40 weeks
Pregnancy
Infant health: weight
Method continuation
Adverse events
Pregnancy: none in Cu-IUD or PVR
groups at 12 months.
No difference in infant weight gain
between groups.
Discontinuation: PVR=65.4/100
women/years, N=54; Cu-IUD=2.3/
100 women-years, N=2. Reasons for
discontinuation PVR: menstrual
problems N=3; vaginal problems
(increased discharge or vaginitis) N=
10; expulsion N=7; ring out ≥48 h
N=12; unpleasant ring use N=13;
other medical reasons N=5.
Complaints higher at all follow-up
visits among PVR vs. Cu-IUD users;
significantly higher at 1, 3, 6 months.
Mean B/S episodes and B/S days:
significantly lower for PVR vs.
Cu-IUD for all follow-up periods
(p≤ .001) . I r regula r b leed ing
significantly lower for PVR vs.
Cu-IUD at 1, 3 months; NS for later
periods. More than 75% PVR
reporting amenorrhea during study
period, significantly higher than
Cu-IUD at all visits (p≤.01).
Strengths:
Clear definition and analysis of
bleeding and spotting patterns
Weaknesses:
Self-reported bleeding
Significant differences in baseline
characteristics between methods:
PVR users slightly more educated;
more PVR users had cesarean section.
Few measures of infant health
High and differential method
d i s c on t i n u a t i o n (PVR=54% ,
Cu-IUD=2.3%). Limited 12 months
data/limited explanation: PVR=31%;
Cu-IUD=60%
II-2, poor
Diaz S, 1997
WHO, CONRAD,
Population Council
Chile
(same protocol as
Sivin 1997)
Prospective cohort study
“treated”
LNG implant (N=120)
PVR (N=187)
POP (N=117)
Cu-IUD (N=122)
Pregnancy
Lactation performance: duration
Infant health: weight
Method continuation
Adverse events
Pregnancies: number of pregnancies/
months of exposure
POP 2/1023
PVR 0/1339
Cu-IUD 0/1410
LNG implant 0/1410
Strengths:
Relatively low loss to follow-up:
PVR=7%, POP=9%, LNG implant=
1%, Cu-IUD= 10%, LAM=0%
Weaknesses:
Self-reported bleeding
II-2, poor
(continued on next page)
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Table 1 (continued)
Author year, source of
support, location
Study design Outcome measures Results Strengths/weaknesses Quality
LAM “untreated” (N= 236)
Initiated 57±3 days postpartum
Lactating, 18–35 years, normal
vaginal delivery of healthy singleton
38–40 weeks
Follow-up days 7–10, 20, 30
postpartum; days 15, 30 after
initiation; monthly through 12
months postpartum
LAM “untreated” 48/1363 (1 before
first episode of bleeding)
Duration of lactation: mean NS across
groups.
Infant weight increase: NS differences
across groups.
Reasons for discontinuation:
Weaning: POP=64%, PVR=80%
Bleeding: LNG implant=2%, other
methods=0%
Bleeding, spotting greater in “treated”
vs. “untreated” group within first 30
days of initiation. LAM significantly
longer in POP, PVR, LNG implant
compared wi th Cu- IUD and
“untreated” (controlled for age,
parity) and PVR significantly greater
than POP, LNG implant.
Several significant differences in
baseline characteristics between
methods: Cu-IUD users older;
lactation users lower parity, lower
BMI, lower weight.
Difficult to determine if some of the
study popula t ion is repor ted
elsewhere (i.e. Diaz 1999).
High attrition in POP, PVR groups:
protocol stipulated stopping at
weaning vs. LNG implant, Cu-IUD.
Few measures of infant health
reported.
PVR use problems resulted in
discontinuation (N=23); not an issue
for other groups.
Sivin I, 1997
USAID, UNFPA,
Population Council
Multicenter study
(9 clinics)
Egypt, USA, Chile,
Singapore, China,
Sri Lanka
(same protocol as
Diaz 1997)
Prospective cohort study
PVR (N=802)
Cu-IUD (N=734)
Initiation 4–9 weeks postpartum
Follow-up 1, 3, 6, 9, 12 months
postmethod initiation
Pregnancy
Lactation performance: number of
episodes
Infant health:
weight
Method continuation
Adverse events
Pregnancy rate at 12 months: 1.5/100
PVR vs. 0.5/100 Cu-IUD.
Mean number breastfeeding
episodes: NS between method groups
at 61, 91, 274 and 365 days. Slightly
higher for PVR group at 183 days
(pb.05).
No difference in infant weight during
year, but significantly higher at
12 months in Cu-IUD group (p=.02)
Discontinuation: significantly higher
for bleeding in PVR group at 6,
12 months pb.001. Overall rates at 6
and 12 months: PVR=52.5, 23.5;
Cu-IUD=74.8, 34.5, respectively.
Bleeding: significantly higher
amenorrhea in PVR group at 1, 6, 9,
12 months (pb.001).
Vaginal complaints (i.e. feeling the
ring): higher in PVR (pb.001)
Abnormal vaginal findings: (i.e.
vaginal discharge, nonspecific
vaginitis, yeast) higher in Cu-IUD
group (pb.01).
Expulsion: PVR=6%; 8.1/100
termination rate. Cu-IUD=0.8% at 6
months, 3.7% at 12 months; 5.6/100
termination rate.
Strengths:
Multiple study locations
Large sample size
Low loss to follow-up: PVR=4.4%,
Cu-IUD=5.7%
Weaknesses:
Most baseline characteristics were
similar between groups. PVR
significantly lower parity; Cu-IUD
higher maternal weight (pb.05) and
higher percentage of vaginal
deliveries (pb.01).
Difference in continuation rates
Large interstudy center differences
II-2, fair
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Study termination for weaning/infant
health higher in Cu-IUD group: 58%
vs. 51% in PVR group (pb.05).
Shaaban M, 1991
WHO, Population Council,
Rockefeller Foundation
Egypt
Prospective cohort study
PVR (N=103)
Cu-IUD T380A (N=83)
Initiated 5–7 weeks postpartum
Follow-up at 12 months postpartum
Pregnancy
Lactation performance:
Time to introduction
of supplementary foods
Infant health: weight
Method continuation
Pregnancy: 1/1007 woman-months in
PVR group, 0/958 woman-months in
Cu-IUD group.
No difference between groups.
No differences in infant weight or
health
Continuation rates at one year: PVR=
66.6%, Cu-IUD=85.5%
No data on population characteristics
Weaknesses:
Baseline characteristics of study
population not presented
Differential continuation rates
Low loss to follow-up: PVR=4%,
Cu-IUD=0%.
Study methodology not adequately
described
II-2, poor
Diaz S, 1985
WHO, Population Council,
USAID, Rockefeller
Foundation, Andrew W
Mellon Foundation, George
J Hecht Funds, The Ford
Foundation UNFPA
Chile
Prospective cohort study
PVR (N=128)
Cu-IUD (N=127)
Placebo injection (N= unknown)
Initiated 60±5 days postpartum
Lactating, 18–35 years, normal
vaginal delivery of healthy singleton
38–40 weeks
Follow-up at 12 months postpartum
(monthly visits to 6, every 2 months
up to 12 months)
Baseline characteristics
Pregnancy
Lactation performance: duration
Infant health: weight
Method continuation
No significant differences in baseline
characteristics.
Pregnancies (woman-months): PVR=
1/739, Cu-IUD=0, placebo=19/677.
No s i g n i f i c a n t d i f f e r e n c e s ;
exclusively breastfeeding at 6
months=57% vs. 58%, at 12
months=11% vs. 20%, for PVR and
Cu-IUD groups, respectively.
Infant weight: No significant
differences in absolute or average
infant weight gain.
Discontinuation: PVR =23, Cu-IUD=
10.
Loss to follow-up: PVR=5, Cu-IUD=
11
Strengths:
Loss to follow-up: PVR=4%,
Cu-IUD=9%
Weaknesses:
Limited information on additional
placebo group
II-2, fair
B/S=bleeding/spotting.
HPV=human papilloma virus.
NS=not significant.
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conducted in Egypt, China, and Chile. According to a large
multicountry study, patterns of infant weight were similar
among women using a PVR or the Cu-IUD through
12 months of observation; however, at 12 months follow-up,
infants whose mothers used a Cu-IUD weighed more [mean
weight: 9528 g (Cu-IUD) vs. 9307 g (PVR)], and the
difference was statistically significant (p=.02) [18]. Finally,
an observational study of Egyptian women reported no
significant differences in “infant health” between PVR and
Cu-IUD users during a 12-month period; however, the
investigator failed to describe the health outcomes that were
collected to define infant health.3.4. Discontinuation/continuation
Discontinuation of self-selected methods prior to the
completion of the included studies was common and
variable. In general, more studies reported higher rates of
discontinuation among women who elected to use the
PVR compared with women who chose the Cu-IUD
[16–18,20,21]. Reasons for discontinuation varied across
the studies. Significantly higher proportions of PVR users
described difficulties using the method compared with
women using other methods. Difficulties cited included
vaginal problems, bleeding irregularities, or other personal
reasons. No serious adverse events occurred or contributed to
the discontinuation rates observed in all studies.3.5. Bone health
One study included in this review examined several
measures of bone health among a small sample (N=129)
of Chilean breastfeeding women. The women self-selected
to use the PVR, the LNG implant, or the Cu-IUD. This
observational study assessed differences between markers
of bone metabolism (calcium, phosphorus, magnesium,
alkaline phosphatases, and hydroxyproline/creatinine) and
bone density (total body, lumbar spine, right femoral neck,
and right trochanter). The participants underwent evalua-
tion of the above described parameters during the
12-month study period and after weaning (6 months for
PVR users and 12 months for Cu-IUD and LNG implant
users). At 1 month postpartum, breastfeeding participants
exhibited lower bone density levels at the lumbar spine
compared with an external nonbreastfeeding comparison
cohort (these women were not enrolled in the study).
However, no differences in bone density measures were
observed after weaning between breastfeeding women
who used the PVR, Cu-IUD, or LNG implant, as well as
the nonbreastfeeding comparison cohort. With the excep-
tion of lower levels of alkaline phosphatases at 6 months
follow-up among PVR users compared with Cu-IUD
users, no other significant differences in markers of bone
metabolism were noted during the study [22].4. Discussion
The seven studies included in this review were assessed to
be of poor (three studies [17,19,20]) to fair (four studies
[16,18,21,22]) methodological quality. Four of the seven
studies were conducted in public sector settings in Latin
America. Results from these studies consistently showed that
use of the PVR did not affect breastfeeding performance or
infant weight gain, and that the PVR was as effective at
preventing pregnancy during 12 months postpartum or
postmethod initiation (depending upon the study design) as
both the highly effective Cu-IUD and LNG implant. The
studies suggested limited evidence that overall infant health
was not affected by PVR use; however, this outcome
measure was poorly defined.
Expanding the use of modern contraceptive methods
among women who breastfeed is a vitally important
individual and public health issue. To ensure that these
advantages are maximized, a variety of safe and effective
contraceptive methods are necessary so that breastfeeding
women are able to choose a method that meets their own
personal preferences, values and circumstances.
Despite the reassuring findings derived from this review,
it is important to recognize several limitations to this small
body of evidence that may limit the generalizability of the
results. None of the included studies were randomized
controlled trials comparing the PVR to nonhormonal
contraceptive methods or to other progestogen-mediated
methods; participants in all of the studies selected their
contraceptive method. While all of the studies relied upon
self-reported/subjective accounts of breastfeeding and bleed-
ing episodes, these outcome measures remain appropriate in
the context of the desired assessments. Although no
significant adverse effects were noted in any studies with
regard to infant weight gain, few measures of other aspects of
infant health were collected and there was limited informa-
tion on the specific measures that were collected. Moreover,
the timing of PVR initiation postpartum within the studies
varied from 29 to 270 days; it is not known whether
breastfeeding performance or infant health measures would
vary depending upon earlier initiation of PVR use. Two
studies experienced high rates of loss to follow-up [20,22].
The study examining the effect of the PVR, LNG implant,
and Cu-IUD on maternal bone turnover and density had a
small sample size [22].
Additionally, there was a notable difference in continu-
ation rates between contraception methods in several studies
[17,18,20,21]; in particular, two studies reported higher rates
of PVR discontinuation compared with other methods
[19,20]. The reasons cited by the participants in these
studies included complaints such as unscheduled vaginal
bleeding, increased vaginal discharge, and ring expulsion. In
addition, participants were instructed to discontinue the PVR
with weaning, which may also partially explain higher
discontinuation rates among these women, particularly when
compared with the Cu-IUD and LNG implant both of which
261S.L. Carr et al. / Contraception 94 (2016) 253–261are long-acting reversible devices. Potential users of the PVR
should thus be counseled appropriately with regard to proper
use and expectations for irregular bleeding patterns and other
minor side effects. Acceptors of the PVR should also be
counseled about transitioning to another effective method of
contraception during the weaning process as the effective-
ness of the PVR in nonbreastfeeding women is not known.
In March 2014, a WHO GDG reviewed the body of
evidence presented in this systematic review, as well as a
Grading Recommendations, Assessment, Development and
Evaluation profile that summarized the strength of the
evidence to assess eligibility for inclusion of the PVR among
postpartum breastfeeding women in the WHO MEC for
Contraceptive Use, 5th Edition. During the deliberations, the
Group noted that additional studies are needed to examine
whether PVR use can be safely initiated prior to 4 weeks
postpartum and whether the contraceptive effectiveness of
the PVR is dependent upon the mother fully breastfeeding.
After consideration of the evidence provided by this
systematic review and discussion among the Group, WHO
issued the following recommendation for use of the PVR:Women who breastfeed and are four or more weeks
postpartum can use the PVR without restrictions (MEC
category 1). The Guideline Development Group advised that
women who use the PVR must be actively breastfeeding (e.g.
at least four breastfeeding episodes per day) to maintain the
efficacy of the method.5. Conclusion
Summary of evidence: direct, level II-2, poor to fair.
In general, evidence from seven prospective observation-
al studies consistently showed that use of the PVR among
women who breastfeed compares favorably to other highly
effective methods of contraception and does not compromise
a woman’s breastfeeding performance nor adversely affect
infant weight gain during the first year postpartum.
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